Biomarker blood test confirms remission in patients with HPV+ oral cancer

byAmerican Society for Radiation OncologyA highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related

Oncology December 18,2023

Biomarker blood test confirms remission in patients with HPV+ oral cancer

byAmerican Society for Radiation OncologyA highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related

Oncology December 18,2023

Patients with cancer, suppressed immune system at high risk for severe COVID if treated with systemic drug therapies

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainPatients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than t

Oncology December 18,2023

Patients with cancer, suppressed immune system at high risk for severe COVID if treated with systemic drug therapies

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainPatients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than t

Oncology December 18,2023

Radiation/cisplatin combination established as standard of care for HPV+ oral cancer

byAmerican Society for Radiation OncologyCombinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial

Oncology December 18,2023

Radiation/cisplatin combination established as standard of care for HPV+ oral cancer

byAmerican Society for Radiation OncologyCombinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial

Oncology December 18,2023

Men with low-/intermediate-risk prostate cancer benefit from fewer, higher-dose radiation treatments

byAmerican Society for Radiation OncologyStereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long

Oncology December 18,2023

Men with low-/intermediate-risk prostate cancer benefit from fewer, higher-dose radiation treatments

byAmerican Society for Radiation OncologyStereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long

Oncology December 18,2023

Variants in BRCA1/2 and MMR genes in children with cancer

by Stefan Zorn, Medizinische Hochschule HannoverProfessor Dr. Christian Kratz, initiator of the international study that investigated the cancer risk of disease-relevant variants in BRCA1/2 and MMR ge

Oncology December 18,2023

Variants in BRCA1/2 and MMR genes in children with cancer

by Stefan Zorn, Medizinische Hochschule HannoverProfessor Dr. Christian Kratz, initiator of the international study that investigated the cancer risk of disease-relevant variants in BRCA1/2 and MMR ge

Oncology December 18,2023

Pelvic lymph node radiation provides significant benefit for prostate cancer patients

byAmerican Society for Radiation OncologyThe first report of a large international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates,

Oncology December 18,2023

Pelvic lymph node radiation provides significant benefit for prostate cancer patients

byAmerican Society for Radiation OncologyThe first report of a large international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates,

Oncology December 18,2023

Radiation therapy cuts low risk of recurrence in half for patients with 'good risk' breast cancer

by NRG OncologyA subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiationtherapy

Oncology December 18,2023

Radiation therapy cuts low risk of recurrence in half for patients with 'good risk' breast cancer

by NRG OncologyA subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiationtherapy

Oncology December 18,2023

Blood test biopsy for kids with brain tumors is simple, safe way to see if treatment is working

byUniversity of California, San FranciscoA new blood test for children with brain tumors offers a safer approach than surgical biopsies and may allow doctors to measure the effectiveness of trea

Oncology December 18,2023

Blood test biopsy for kids with brain tumors is simple, safe way to see if treatment is working

byUniversity of California, San FranciscoA new blood test for children with brain tumors offers a safer approach than surgical biopsies and may allow doctors to measure the effectiveness of trea

Oncology December 18,2023

Barriers to early clinical trial access for adolescents and young adults still exist

byEuropean Society for Medical OncologyYoung cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congre

Oncology December 18,2023

Barriers to early clinical trial access for adolescents and young adults still exist

byEuropean Society for Medical OncologyYoung cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congre

Oncology December 18,2023

How cancer cells die: Scientists explore new pathways of pyroptosis, killer kin of apoptosis

by Delthia Ricks , Medical XpressLymphoid BLaER1 cells undergo PANX1-dominant lysis. (A to C) BLaER1 cells were treated with topoisomerase poisons doxorubicin (2 μM) or etoposide (50 μM) for 24 hours.

Oncology December 18,2023

How cancer cells die: Scientists explore new pathways of pyroptosis, killer kin of apoptosis

by Delthia Ricks , Medical XpressLymphoid BLaER1 cells undergo PANX1-dominant lysis. (A to C) BLaER1 cells were treated with topoisomerase poisons doxorubicin (2 μM) or etoposide (50 μM) for 24 hours.

Oncology December 18,2023